Valeant Pharmaceuticals Responds To Erroneous Report

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. NVDA
2. CRWV
3. SPY
4. IRON
5. EYPT
6. SLGN
7. STLD
8. CHRD
9. AMZN
10. CLF

Go back to Valeant Pharmaceuticals Responds To Erroneous Report

Deutsche Bank 'Remains Cautious' on Valeant (VRX); Analyst Maintains Hold Rating

October 22, 2015 9:37 AM EDT

Deutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $204. Analyst Gregg Gilbert said he remains cautious on the stock given uncertainties related to the drug pricing, its specialty pharmacy distribution model, and related government inquiries.

Gilbert explained, "VRX shares have been under significant pressure, most recently following allegations related to its specialty pharmacy distribution model. While it is difficult to predict how more conservative pricing behavior and other potential changes could affect revenue growth, we thought it would be helpful to look at... More